Business
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene’s clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Company”), today announced the appointment of
About this update from Moonlake Immunotherapeutics
[{"type":"image","alt":"ImageneBio, Inc.","displaySize":"","headline":null,"caption":"ImageneBio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":126,"height":48,"url":"https://media.zenfs.com/en/globenewswire.com/8676856806afc907243b07503009d2bc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8_3nel2HRyqI7lDiYMAfoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/8676856806afc907243b07503009d2bc","width":126,"height":48}},"lazy":false},{"type":"text","content":"Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership","length":132,"tagName":"p"},{"type":"text","content":"Will build and lead Imagene’s clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis","length":124,"tagName":"p"},{"type":"text","content":"Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe","length":100,"tagName":"p"},{"type":"text","content":"SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Company”), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be focused on driving execution of the Phase 2b ADAPTIVE trial in atopic dermatitis (AD) and building Imagene’s clinical organization.","length":464,"tagName":"p"},{"type":"text","content":"“Welcoming Ben to the Imagene team is the next step in executing our plans to create a focused, clinically excellent company. Ben’s expertise in autoimmune and inflammatory diseases within and beyond medical dermatology, including his previous work on OX40 signaling inhibitors, is an incredible asset for our program. A recognized people leader, Ben will build and lead our clinical team, which will be essential as we focus on the execution of our Phase 2b ADAPTIVE trial in AD.” commented Kristin Yarema, PhD, Chief Executive Officer of Imagene.","length":548,"tagName":"p"},{"type":"text","content":"Dr. Porter-Brown is an experienced drug developer with over 20 years of experience, primarily in autoimmune and inflammatory diseases, including in the OX40-OX40L space. He joins Imagene after most re...